J. Mark Junewicz Email & Phone Number

GNOMX was founded to commercialize host response epigenetic diagnostics based on research funded by a $46 million DARPA ECHO contract to an academic consortium led by the Icahn School of Medicine at Mount Sinai, Yale University School of Medicine, Princeton University, and the University of Pittsburgh School of Medicine. The DARPA-sponsored research developed patent-pending, beyond state-of-the-art blood epigenetic tests that rapidly diagnose, determine time of exposure, and monitor long-term effect of infections and other exposures.

Private investment banking services for companies in the Life Sciences Industry - Biopharmaceuticals and Medical Devices. Provide M&A, product licensing, business development and IPO advisory services. Also arrange private equity financings.Privileged to have advised companies with game-changing products like Kos Pharmaceuticals (Niaspan® for lipid management), acquired by Abbott Labs; Richwood Pharmaceuticals (ADDERALL® for ADHD), acquired by Shire plc; Animas Corporations (superior products and services for better management of insulin-requiring diabetes), acquired by J&J: and Medicis Pharmaceuticals (leading U.S. dermatology company), acquired by Valeant Pharmaceuticals.

New York, Ny, Us

MSIP facilitates the transfer of discovery from the laboratory to the marketplace, linking Mount Sinai innovations with industry. 

Ignyta, a precision medicine oncology biotech company, was acquired by Roche Holdings in February 2018 for $1.7 billion.

New York City, Us

Senior investment banker covering large cap clients in Life Sciences.

New York, Ny, Us

Senior investment banker to large cap companies including IBM, Time-Warner, Schering-Plough and Deere & Company. Completed over 200 M&A and financing transactions for clients. Also responsible for training newly-hired investment banking associates and analysts.

M.B.A, Finance

B.S. Economics, Cum Laude, Finance